Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving gefitinib
together with docetaxel and radiation therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel when
given together with gefitinib and radiation therapy in treating patients with stage III
non-small cell lung cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University Wake Forest University Health Sciences